Security key
98422T100
Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (XLO)
CUSIP: 98422T100
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 12,460,895
- Total 13F value
- $13,460,257
- Share change
- -3,705,477
- SEC-reported price per share
- $1.08
- Number of holders
- 30
- Value change
- -$2,676,053
- Number of buys
- 11
- Number of sells
- 13
- Shares outstanding
- 6,426,426
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
30
Top holders
10
XLO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Xilio Therapeutics, Inc. SEC filings
Xilio Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98422T100
Recent filing periods:
Ownership snapshot
Top reported holders of XLO - Xilio Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Dec 2023
3/4/5
13F
Lead comparable stake: 44%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 44%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bain Capital Life Sciences Investors, LLC's linked filing trail.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
44%
Atlas Venture Life Science Adviso...
43%
FMR LLC
30%
Octagon Capital Advisors LP
28%
TAKEDA PHARMACEUTICAL CO LTD
23%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
3/4/5
13F
10%+ Owner · Company
|
44%
from 13F
|
$2,328,493
2,805,413 shares
|
— | 08 Dec 2021 |
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
43%
|
$1,517,639
2,759,344 shares
|
— | 31 Dec 2023 |
| FMR LLC |
3/4/5
13F
Other* · Company
|
30%
from 13F
|
$1,583,366
1,907,670 shares
|
— | 26 Oct 2021 |
| Octagon Capital Advisors LP |
13F
Company
|
28%
|
$981,750
1,785,000 shares
|
— | 31 Dec 2023 |
| TAKEDA PHARMACEUTICAL CO LTD |
3/4/5
13F
10%+ Owner · Company
|
23%
from 13F
|
$1,224,350
1,475,121 shares
|
— | 26 Oct 2021 |
| RiverVest Venture Management LLC |
13F
Company
|
22%
|
$792,794
1,441,444 shares
|
— | 31 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
30
Shares
12,460,895
Rows available
30
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2026 Across Filers
Q1 2026 holders
1
Q1 2024 holders
30
Holder diff
29
| Investor | Q1 2026 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend